May 16, 2022

Presentations convey essential technological and scientific knowledge regarding AAV gene therapy and advancements across key disease areas  CEO Sheila Mikhail and President of Therapeutics, Katherine A. High will be featured speakers Research Triangle Park, N.C. – May 16, 2022 –Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that the Company will present 11 abstracts at the upcoming American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16 – 19, 2022 at the Walter E. Washington Convention Center  in Washington, D.C.  The ASGCT Annual Meeting is the premier event for professionals in gene and cell therapy where noted industry professionals gather to learn from the latest advances in scientific and clinical research and cell and gene technology. Abstracts being presented by AskBio team members include new data and insights regarding Adeno Associated Virus (AAV) gene therapy, T-cell immune response to empty capsid technologies, inducible promoters and gene expression, and doggybone DNA (dbDNA) as well as data for AskBio’s key clinical development programs, including Pompe Disease, Parkinson’s Disease and Congestive Heart Failure.   AskBio will make seven oral presentations and four poster presentations. CEO Sheila Mikhail and President of Therapeutics, Katherine A. High will be featured speakers during the event. “Having 11 abstracts accepted for presentations reflects the significant progress made by our teams across a broad front,” commented Kathy High, President, Therapeutics for AskBio. “I am very proud of the groundbreaking work by our research and clinical teams as we continue to advance our therapeutic pipeline and AAV gene therapy research and manufacturing.”  Jude Samulski, Chief Science Officer and Co-Founder for AskBio said, “These presentations underscore our commitment to advancing the science of gene therapy to tackle many of the biggest challenges in the space today, including manufacturing, dosing, immune response and treatment efficacy. We hope that, together with our many colleagues in cell and gene therapy space, we can make a profound difference in the lives of patients around the world who are waiting for transformative gene therapies.”  AskBio’s presentations at ASGCT include:  Monday, May 16 Oral PresentationAbstract 37: Functional Assessment of T-cell Responses to AAV8 Empty Capsids in Healthy VolunteersSession: Immune Responses to AAV Vectors 10:30 am – 11:45 am, Room: 102 Oral PresentationAbstract 28: A First-in-Human Phase 1 Clinical Gene Therapy Trial for the Treatment of Heart Failure Using a Novel Re-Engineered Adeno-Associated Vector Session: Cardiovascular and Pulmonary Diseases 11:45 am – 12 PM, Room 206 Featured Speaker Launching Innovation Into Gene Therapy Companies Session: Part 2: Translating Science Into Medicine: Moving from Bench to Startup (Organized by the Bioindustry & Translational Science Committees) Sheila Mikhail, JD, CEO and Co-Founder, AskBio 1:30–2:18 PM Room: Salon G Tuesday, May 17 Oral Presentation: Abstract 434: Characterization of Alternative Reading Frame Proteins Generated from AAV Cassettes Session: Discoveries in Fundamental AAV Biology 4:00–4:15 PM, Ballroom A Poster Presentation: Abstract 796: Safety and preliminary efficacy of neurosurgical AAV2-GDNF delivery for Parkinson’s disease Session:  Gene and Cell Therapy Trials in Progress 5:30PM, Hall D            Poster Presentation: Abstract 711: ...read the news